Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia

• DOI: 10.1136/bjo.2006.099887
• Publication Date: 2006-08-17T00:13:40Z
• Authors: H Sakaguchi; Y Ikuno; F Gomi; M Kamei; M Sawa; M Tsujikawa; Y Oshima; S Kusaka; Y Tano
• Keywords: Adult; Male; Vascular Endothelial Growth Factor A; Fovea Centralis; Visual Acuity; Antibodies, Monoclonal; Angiogenesis Inhibitors; Middle Aged; Antibodies, Monoclonal, Humanized; Choroidal Neovascularization; 3. Good health; Bevacizumab; 03 medical and health sciences; Treatment Outcome; 0302 clinical medicine; Myopia, Degenerative; Humans; Female; Aged; Follow-Up Studies

To assess the efficacy and safety of an intravitreal injection bevacizumab (Avastin(R)) for myopic choroidal neovascularisation (mCNV).Intravitreal (1 mg) was injected into eight eyes patients with mCNV in this non-randomised, interventional case series. The best-corrected visual acuity (BCVA) measured optical coherence tomography (OCT) fluorescein angiography findings were examined before after treatment. minimum follow-up time 3 months.The mean BCVA 0.26 treatment 0.51 at last visit (p = 0.009). improved to two or more lines six (75%) remained same (25%). Leakage from on decreased seven (87.5%). area 0.049) foveal thickness OCT images significantly 0.027) No major complications developed.Intravitreal seems be effective safe mCNV.